Menu
Menu
What happens when a world-class biologist decides that academic research isn't moving fast enough for patients?
In this episode of Decoded, Dr. Jurgi Camblong speaks with Dr. Keith Flaherty, a physician-scientist who bridges the gap between academia, biotech, and pharma to bring smarter therapies to patients, faster.
Fascinated by the "wiring of cells," Keith followed his intuition during the cell biology boom of the early 90s, eventually finding his focus in oncology. Today, he is rewriting the rules of drug development. He didn't stop at academia; he felt the need to found companies like Loxo Oncology and Scorpion Therapeutics to execute faster.
You’ll hear about:
This episode explores how cancer drug development is evolving from trial-and-error to data-driven design. It proves that real innovation in oncology isn’t just about discovering new targets, but building an ecosystem where discovery, trials, evidence, and access actually work together.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
